In the United States, Medicare covers 80% of the cost of macular degeneration screening and anti-VEGF injections such as aflibercept, ranibizumab, bevacizumab, and verteporfin for Medicare beneficiaries. The gene discussed is VEGFA; the disease is macular degeneration.